1. 2505 TMPRSS2-ERG in blood and docetaxel response in metastatic castration-resistant prostate cancer. (September 2015) Authors: Reig, O.; Marín-Aguilera, M.; Carrera, G.; Jimenez, N.; García-Recio, S.; Gaba, L.; Pereira, M.V.; Fernandez, P.; Prat, A.; Mellado, B. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S475 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy. (3rd July 2018) Authors: Xipell, M.; Victoria, I.; Hoffmann, V.; Villarreal, J.; García-Herrera, A.; Reig, O.; Rodas, L.; Blasco, M.; Poch, E.; Mellado, B.; Quintana, L. F. Journal: Oncoimmunology Issue: Volume 7:Number 7(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Different degree of epithelial–mesenchymal transition phenotype in docetaxel and cabazitaxel castration-resistant prostate cancer cells. (December 2016) Authors: Jiménez, N.; Marín-Aguilera, M.; Reig, O.; Nadal, L.; García-Recio, S.; Pereira, M.V.; Prat, A.; Mellado, B. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗